| Literature DB >> 22044742 |
Tamsin R Sheen1, Courtney K Cavaco, Celia M Ebrahimi, Marilyn L Thoman, Sam D Sanderson, Edward L Morgan, Kelly S Doran.
Abstract
The emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is a serious health concern worldwide that requires new therapeutic approaches that extend beyond the development and use of new antibiotics. In this study, a conformationally biased, response-selective agonist of human C5a, known as EP67, was used to induce host innate immunity as a therapeutic method of reducing CA-MRSA infections. Using a murine model of dermonecrosis we show that EP67 treatment effectively limits CA-MRSA infection by promoting cytokine synthesis and neutrophil influx. In contrast, EP67 was ineffective in reducing lesion formation in C5a receptor (CD88(-/-)) knockout mice, indicating that EP67 activates host innate immunity by engagement of CD88 bearing cells. These results suggest that EP67 may serve as a novel immunotherapeutic for prevention and treatment of CA-MRSA dermal infection.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22044742 PMCID： PMC3229650 DOI： 10.1016/j.vaccine.2011.10.054
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641